Open access
Sep 2026
63 Th17 Signature Predicts Response to Dual Checkpoint Blockade in Metastatic Renal Cell Carcinoma
Abstract Background Combination immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 antibodies improves outcomes in metastatic renal cell carcinoma (mRCC), yet 40–60% of patients fail to achieve meaningful responses. Robust biomarkers that predict deep and durable responses are lacking. We aimed to define syste...
S. Guglietta, A. Bärenwaldt, Anthony Sonrel et al.
· The Oncologist · 0 citations